Importance of rigorous evaluation in comparative biomarker studies

James L Januzzi*, Roland R J van Kimmenade

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Following the introduction of B-type natriuretic peptide (BNP) and its amino-terminal equivalent (NT-proBNP), the use of biomarkers for the evaluation and management of heart failure (HF) has grown. Indeed, natriuretic peptide testing for diagnosis and prognosis recently earned a Class I Level of Evidence: A in the 2013 American Heart Association/American College of Cardiology clinical practice guidelines for HF (2). Although it took years to develop such support, this is indeed the proper recognition of the clinical role played by these important biomarkers.
Original languageEnglish
Pages (from-to)167-9
Number of pages3
JournalJournal of the American College of Cardiology
Issue number2
Publication statusPublished - 21 Jan 2014


  • Cardiomyopathies
  • Female
  • Galectin 3
  • Heart Failure
  • Humans
  • Male
  • Receptors, Cell Surface
  • Risk Assessment


Dive into the research topics of 'Importance of rigorous evaluation in comparative biomarker studies'. Together they form a unique fingerprint.

Cite this